Legend BiotechLEGN -0.03%71 PS Ratio is 4.85 as of Jul. 03, 2026, which is 91% below its 10-year median of 52.08. GuruFocus rates LEGN with a GF Score™ of 71/100 and a GF Value™ of $99.13 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Legend Biotech ranks better than 67.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Legend Biotech's share price is $29.93.
Legend Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.17. Hence, Legend Biotech's PS Ratio for today is 4.85.
The historical rank and industry rank for Legend Biotech's PS Ratio or its related term are showing as below:
LEGN'
s PS Ratio Range Over the Past 10 Years
Min: 2.95 Med: 52.08 Max: 121.06
Current: 4.84
During the past 8 years, Legend Biotech's highest PS Ratio was 121.06. The lowest was 2.95. And the median was 52.08.
LEGN's PS Ratio is ranked better than 67.42% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs LEGN: 4.84
During the past 12 months, the average Revenue per Share Growth Rate of Legend Biotech was 55.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 96.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 64.90% per year.
During the past 8 years, Legend Biotech's highest 3-Year average Revenue per Share Growth Rate was 96.50% per year. The lowest was -0.10% per year. And the median was 36.60% per year.
Back to Basics: PS Ratio
Legend Biotech (NAS:LEGN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Legend Biotech PS Ratio Related Terms
Legend Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Legend Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Legend Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Legend Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Legend Biotech's Share Price of today is $29.93. Legend Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Legend Biotech (LEGN) has a PS Ratio of 4.85 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Legend Biotech and its competitors. This is 91% below median its historical median of 52.08. Over the past decade, Legend Biotech's PS Ratio has ranged from 2.95 to 121.06. According to the industry distribution chart, Legend Biotech ranks #304 out of 933 companies in the Biotechnology industry, placing it in the top 32.6%.
Is Legend Biotech's PS Ratio too high?
Legend Biotech's current PS Ratio of 4.85 is 91% below median its 10-year median of 52.08. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 121.06. The Biotechnology industry median PS Ratio is 9.64. Legend Biotech's value of 4.85 is 49.7% below this industry median. Based on the distribution chart, Legend Biotech ranks #304 out of 933 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Legend Biotech has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's PS Ratio compare to TVTX and ORKA?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #304 out of 933 companies for PS Ratio. This puts Legend Biotech in the upper half of its industry. The industry median PS Ratio is 9.64. Legend Biotech's value of 4.85 is 49.7% below this benchmark. Historically, Legend Biotech's own PS Ratio has ranged from 2.95 to 121.06 over the past decade. While the company's 10-year median is 52.08 vs. the industry median of 9.64, Legend Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Legend Biotech's current PS Ratio of 4.85 is 49.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Legend Biotech and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Legend Biotech's current PS Ratio is 4.85, which is 91% below median its own 10-year median of 52.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.13, compared to a current price of $29.93 — trading 69.8% below its estimated fair value. The current PS Ratio is 4.85, which is 91% below median its 10-year median of 52.08 and 49.7% below the Biotechnology industry median of 9.64. Legend Biotech's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Legend Biotech (LEGN), the current PS Ratio is 4.85 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $29.93 is trading 69.8% below its estimated GF Value™ of $99.13.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
PS Ratio: 4.85 (91% below median its 10-year median of 52.08)
GF Value™: $99.13 vs. price of $29.93 (69.8% below fair value)
Industry Position: 49.7% below the Biotechnology median (#304 of 933)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
71GF Score
Get the complete analysis for LEGN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
